Login
$CLOV
$4.56 -$0.04 (0.87%) Close

Company Executives

$CLOV Management Team

Mr. Ryan Schmidt

Investor Relations

Age -
Compensation -
Sex Male

Mr. Peter Kuipers

Chief Financial Officer

Age 53
Compensation $4.984M USD
Sex Male

Mr. Vivek Garipalli

Executive Chairperson of the Board

Co-Founder

Age 46
Compensation $389.6M USD
Sex Male

Mr. Andrew Toy

Chief Executive Officer

Co-Founder

Director

Age 46
Compensation $9.477M USD
Sex Male

Mr. Brady Priest

Chief Executive Officer - Home Care

Age 49
Compensation $4.455M USD
Sex Male

Ms. Jamie Reynoso

Chief Executive Officer - Medicare Advantage

Age 56
Compensation $4.792M USD
Sex Female

Mr. Conrad Wai

Chief Executive Officer of Counterpart Health

Inc

Age 44
Compensation $4.466M USD
Sex Male

Ms. Karen Soares

General Counsel

Corporate Secretary

Age 47
Compensation $1.466M USD
Sex Female

Dr. Shelly Gupta

Chief Medical Officer

Age -
Compensation -
Sex Male
Directors
7
serving now
Independent
5 of 7
stated in the proxy
Average tenure
5.7 years
from year joined
CEO also chairs the board
No
Vivek Garipalli
Director Age On board Independent Committees Other public boards 2025 pay Source
Andrew Toy
47 2018
8 years
Not independent None stated None stated Paid as CEO
Vivek Garipalli
47 2014
12 years
Not independent None stated None stated Not stated
Carladenise Armbrister Edwards
56 2022
4 years
Independent None stated None stated Not stated
Demetrios L. Kouzoukas
50 2021
5 years
Independent
Audit Committee
None stated $301,096
Anna U. Loengard
57 2022
4 years
Independent
Clinical Committee · Chair
None stated $278,596
William G. Robinson, Jr.
61 2021
5 years
Independent
Talent and Compensation Committee · Chair
None stated $286,096
Thomas L. Tran
69 2024
2 years
Independent
Audit Committee · Chair
None stated $275,179

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Apr 28, 2026
Vivek Garipalli
Executive Chairman and significant stockholder of the Company
$4.4 million
2025

Hospital contracts for inpatient and hospital-based outpatient services with CarePoint Health, which Mr. Garipalli ultimately held and controlled

With CarePoint Health System Open in proxy
Vivek Garipalli
Executive Chairman and significant stockholder of the Company; has an indirect interest in Medical Records Exchange, LLC
$1.5 million
2025

Agreement for administrative services related to medical records retrieval via Credo's electronic applications and web portal platform

With Medical Records Exchange, LLC Open in proxy
Vivek Garipalli
Executive Chairman and significant stockholder of the Company; member of the board of directors of Thyme Care
$8.3 million
2025

Oncology benefit management engagement for concierge cancer coordination services and provider network development, amended effective April 1, 2023; $6.6 million payable to Thyme Care as of December 31, 2025

With Thyme Care, Inc. Open in proxy
Vivek Garipalli
Executive Chairman and a significant stockholder of the Company; indirectly owns 25% of Goldenscript through an investment arm
Minimum annual fee of approximately $1.2 million
April 2026

Agreement for medication therapy management and pharmacogenomic (PGx) testing services, with warrants to purchase approximately 910,600 shares of GoldenScript common stock received by the Company

With GoldenScript, Inc. Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support